Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:56:103-22.
doi: 10.1146/annurev-pharmtox-010715-103633.

RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?

Maggie L Bobbin  1   2 , John J Rossi  3
Affiliations
Review

RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?

Maggie L Bobbin et al. Annu Rev Pharmacol Toxicol. 2016.

Abstract

A resurgence in clinical trials using RNA interference (RNAi) occurred in 2012. Although there were initial difficulties in achieving efficacious results with RNAi without toxic side effects, advances in delivery and improved chemistry made this resurgence possible. More than 20 RNAi-based therapeutics are currently in clinical trials, and several of these are Phase III trials. Continued positive results from these trials have helped bolster further attempts to develop clinically relevant RNAi therapies. With a wide variety of disease targets to choose from, the first RNAi therapeutic to be clinically approved is not far off. This review covers recently established and completed clinical trials.

Keywords: clinical trials; dsiRNA; miRNA; shRNA; siRNA.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources